Q-omics provides the consensus-scored FUOM profile across patient tissues and cancer cell-line models. FUOM expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, FUOM is differentially expressed in 13, with the highest sampling consensus in KIRP. Additionally, FUOM RNA expression shows 17,266 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight ACC, KIRP, and DLBC as cancer lineages where FUOM shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FUOM — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FUOM survival associations across molecular data types. FUOM RNA expression shows survival associations in the most cancer types (20), followed by mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FUOM RNA expression–survival associations across cancer types. High FUOM expression shows unfavorable associations in ACC, COAD, HNSC, LGG and PAAD, but favorable associations in LIHC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for FUOM RNA expression.
This table summarizes FUOM tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRP for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for FUOM. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FUOM shows lower tumor expression in KIRP, KICH, LUAD, BRCA and CHOL and higher tumor expression in STAD. The KIRP box plot shows higher FUOM RNA expression in normal versus tumor tissue (log2 FC = −2.178, t-test p < 0.001).
This table shows molecular features associated with FUOM in patient tissues and cancer cell lines. In patient samples, FUOM shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set. In cancer cell lines, FUOM RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
